Formulary guidance and transparency from P&T to point of care


Reality Check on Cervical Cancer

Market access for cervical cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 37% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In September 2020, the FDA expanded the use of Roche’s CINtec PLUS Cytology test to help clinicians determine which women who test positive for human papillomavirus (HPV) via cobas 6800/8800 Systems require further diagnostic procedures to prevent disease progression
  • Key Findings: Drugs in the market basket have good coverage across payers and lines of business. The majority of payers have policies in place to ensure standard of care is met and appropriate biomarker testing for targeted therapy is conducted

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.